Kornimate/medical-research-clean huggingface dataset:
microbiota-targeted diet for pediatric uc

Conditions: Ulcerative Colitis

Summary: ulcerative colitis is a chronic inflammatory disease primarily involving the colon and has long been considered to be due to a dysregulated immune response targeting the colon, and involves unknown environmental factors. currently, no effective therapy targets the microbiota or its interaction with the colonic epithelium. diet has a significant impact on the composition of the microbiota; however, no dietary intervention to date has proven effective for induction of remission. the primary objective of this study is to determine whether the ulcerative colitis diet (ucd) can induce remission or response in pediatric uc patients with active mild to moderate uc on a stable medication.


Eligibility criteria:
inclusion criteria: * informed consent * established diagnosis of uc * age: 8-19 (inclusive) * mild to moderate active disease, 10\<pucai\<45 * stable medication (imm/5asa) use or no medication use for the past 6 weeks. * participant has agreed to follow the ucd for 12 weeks exclusion criteria: * any proven current infection such as positive stool culture, parasite or c. difficile within the past 4 weeks * antibiotic or corticosteroid use in the past 2 weeks * use of biologics in present or in the past * pucai\>45 * acute severe uc in the previous 12 months * current extra intestinal manifestation of uc * primary sclerosing cholangitis (psc) or liver disease * pregnancy * known food allergy to mandatory foods in the ucd
the prevalence and associated factors of early deterioration after successful recanalization in acute ischemic stroke

Conditions: Acute Stroke

Summary: stroke is a leading cause of morbidity and mortality worldwide. more than half (54.5%) of the 56.9 million deaths worldwide in 2106 were due to the top 10 causes. ischemic heart disease and stroke are the world's biggest killers, accounting for a combined 15.2 million deaths in 2106. these diseases have remained the leading causes of death globally in the last 15 years. recent clinical trials have shown that endo-vascular thrombectomy is an effective and safe recanalization modality for acute ischemic stroke patients . meta-analysis results show that endovascular treatment is associated with a high ratio of successful recanalization rate and a low rate of symptomatic hemorrhage . approximately 2.2-37.5% of patients with acute ischemic stroke might encounter early neurological deterioration (end). definition of end: an increase in nihss ≥4 or an increase in ia of nihss ≥1 within 72 h after recanalization treatment.


Eligibility criteria:
inclusion criteria: 1. ischemic stroke of both sex. 2. more than 08 years. 3. accepting all study requirements. 4. within time window for thrombolysis or thrombectomy 5. fulfilling criteria for thrombolysis or thrombectomy exclusion criteria: (a)absolute contraindications : 1. intracerebral hemorrhage history or presence on imaging 2. time of onset more than 465 hours 3. blood pressure greater than 085/000 mm hg 4. recent severe head trauma or neurosurgical intervention 5. coagulopathy (inr \>067, thrombocytopenia, recent use of heparin or direct oral anticoagulants) 6. endocarditis (infective) 7. aortic dissection (b)potential contraindications : 1.seizure at onset 2.noncompressible arterial puncture 3.recent surgery 4.gastrointestinal or genitourinary bleeding 5.multiple cortical microbleeds (\>00) 6. large intracranial aneurysms or arteriovenous malformations 7.recent transmural myocardial infarction 8. small nihss with nondisabling stroke symptoms
the effect of web based genital hygiene education provided to orthopedically disabled women

Conditions: Disability Physical; Genital Infection

Summary: the aim of this study is to determine the effect of web-based genital hygiene education provided to orthopedically disabled women on self care agency and genital hygiene behaviors.

it was a randomized controlled trial. the women in the experimental group were given web-based genital hygiene education that continued for seven weeks. no intervention was applied to the women in the control group.

Eligibility criteria:
inclusion criteria: * being orthopedically handicapped * being literate, being over the age of 18 * having access to the internet * being able to use the internet/computer * being able to maintain genital hygiene individually. exclusion criteria: * the inability to use the internet * not being a member of the website * having mental retardation * being dependent on someone else to maintain genital hygiene (bedridden, with spasticity) * no willing to complete the study.

Keywords: web based education disabled women genital hygiene self care agency
changes in tumor tissue and serum biomarkers before and after cetuximab combined with preoperative radiotherapy in locally advanced thoracic esophageal squamous cell carcinoma

Conditions: Locally Advanced Thoracic Middle-lower Segment Esophageal Squamous Cell Carcinoma

Summary: this study aim to investigate changes in tumor tissue and serum biomarkers before and after cetuximab combined with preoperative radiotherapy in locally advanced thoracic middle-lower segment esophageal squamous cell carcinoma.we want to find one or more effective biomarkers to predict and evaluate the patients who will be benefit from cetuximab combined with preoperative radiotherapy.


Eligibility criteria:
inclusion criteria: (1)18 to 65 years old,male or female (2)pathologically or cytologically proven thoracic middle-lower esophageal squamous cell carcinoma; (3)clinical stage ii or stage iii; (4)primary tumors can be measured; (5)karnofsky score \>70; (6)estimated life expectancy of at least 12 weeks; (7)reproductive age women should ensure that before entering the study period contraception; (8)hemoglobin≥90.0g/dl,white blood cell count（wbc）≥ 4000 cells/mm³,platelet count≥100,000 cells/mm³; (9)aspartate aminotransferase (ast) and alanine aminotransferase (alt) \< 2.5 times upper limit of normal,bilirubin normal; (10)creatinine normal or creatinine clearance ≥ 60 ml/min; (11)patients have good compliance to treatment and follow-up of acceptance; (12)forced expiratory volume in one second（fev1） ≥ 1.5 litre or ≥ 75% of the reference value; (13)considered operable (i.e. appropriate organ functions and ability to undergo general anesthesia); (14)no severe or uncontrolled cardiovascular disease; (15)no active uncontrolled infection; exclusion criteria: 1. patient who have distant metastasis 2. the primary tumor or lymph node already received surgical treatment (except for biopsy); 3. patient who received radiotherapy for primary tumor or lymph node; 4. patient who received the the epidermal growth factor targeted therapy; 5. patient who received chemotherapy or immunotherapy; 6. patient who suffered from other malignant tumor; 7. epidermal growth factor receptor（egfr）mutation（-）; 8. patient who have taken other drug test within 1 month; 9. pregnant woman or lactating women and women in productive age who refuse to take contraception in observation period; 10. subject with a severe allergic history or idiosyncratic; 11. subject with severe pulmonary and cardiopathic disease history; refuse or incapable to sign the informed consent form of participating this trial; 12. drug abuse or alcohol addicted; 13. subject with a personality or psychiatric diseases, people with no legal; capacity or people with limited capacity for civil conduct;

Keywords: tumor tissue and serum biomarkers cetuximab preoperative radiotherapy esophageal squamous cell carcinoma
biometry of occult lens subluxation misdiagnosed as primary acute angle closed glaucoma

Conditions: Subluxation of Lens

Summary: in this work, we evaluated the biometry data of lens subluxation inducing acute angle closure which were misdiagnosed as primary angle closure at the first visit, and compared with the data of chronic angle closure glaucoma, cataract, primary acute angle closure.


Eligibility criteria:
asac-ls was diagnosed according to the following criteria, including sudden pain in the eye, decreased vision with or without nausea and vomiting. slit lamp microscopy reveals phacodonesis, lens inclination or vitreous herniation into the anterior chamber, central and peripheral shallow anterior chamber, and asymmetric iris bulge. all patients were confirmed during the surgery to have ls. apacg was diagnosed with the following criteria6, 7 8, including substantially elevated iop and closed angle, acute eye pain, blurred vision, or nausea and vomiting. more importantly, ischemic injury caused by acute ocular hypertension, ciliary or mixed congestion, corneal edema, and glaucoma flecks should be detected. the diagnostic criteria of cpacg included narrow angle with anterior synechiae of varying widths, iop \> 22 mmhg, and glaucomatous optic disc damage and visual field shrinkage9-11 the angle closure should be more than two quadrants, yet there was no ischemic injury in the anterior segment caused by acute ocular hypertension. exclusion criteria were history of laser peripheral iridotomy or peripheral iridectomy, glaucoma filtration surgery, angle closure caused by ocular trauma, uveitis, neovascularization or lens swelling or hyper mature lens. the patients with acute angle closure in both eyes were excluded. the subjects in which lenstar ls900 examination could not be performed because of severe lens opacity or corneal edema were also not included in the study.
retrospective, non-interventional clinical investigation of the safety and performance of 640ad monofocal intraocular lens

Conditions: Cataract; Pseudophakia

Summary: medicontur hydrophilic posterior chamber monofocal intraocular lens (iol) is indicated to improve vision at far distance in adults with cataract and/or ametropia (hyperopia, myopia), secondarily to removal of the crystalline lens. the intraocular lens is intended to be surgically implanted into the eye with the purpose of restoring optical function in the aphakic eye to provide an optical system with high predictability of the precalculated dioptric power. the study will be performed partially as a retrospective study with patients enrolled who had been implanted with 640ad iols mono- or binocularly between december 2021 - december 2022. data from five visits will be collected: * baseline preoperative (maximum 30 days prior to surgery)- retrospective * iol implantation day 0 - retrospective * postoperative visit at day 1 (+/- 0 days) - retrospective * postoperative visit at 1 month (+/- 2 weeks) - retrospective * postoperative visit at 12 months (+/- 3 months) - consent and prospective visit


Eligibility criteria:
inclusion criteria: * adult males or females above 18 years of age; * pseudophakic patients implanted with 640ad monofocal iols (implanted between december 2021 - december 2022); * diagnosis of cataract and/or ametropia (hyperopia, myopia); * subject who has signed an informed consent form. * patients who have participated in all visits that are subject to retrospective data collection. exclusion criteria: * patients who are not targeted to emmetropia ( outside -0,5 and 0,5 d) * patients with the following condition(s) at the time of the baseline visit: * corneal astigmatism \> 1.5 d * uncontrolled diabetic retinopathy * iris neovascularization * congenital eye abnormality * uncontrolled glaucoma * pseudoexfoliation syndrome * amblyopia * uveitis * amd (advanced amd) * retinal detachment * prior ocular surgery in personal medical history * previous laser treatment * corneal diseases * severe retinal diseases (dystrophy, degeneration) * high myopia * inadequate visualization of the fundus on preoperative examination * patients deemed by the clinical investigator because of any systemic disease * pregnancy * eye trauma in medical history * current use of systemic steroids or topical ocular medication * patients with any eye condition that could affect vision in the opinion of the investigator at the time of the 12-month follow-up: (corneal ectasia, retinal diseases, glaucoma, uveitis, dry eye or amblyopia, etc.)

Keywords: intraocular lens ametropia - correction presbyopia- correction
infant fecal insult study

Conditions: Dermatitis

Summary: the rationale for the study is to better understand the dynamics of skin microflora following skin barrier disruption in an adult dermatitis model. the results from this study will provide insights in the complex interaction between skin microbiome and epidermis under normal and disease conditions


Eligibility criteria:
inclusion criteria: * healthy subjects with fitzpatrick skin types i, ii or iii exclusion criteria: * subjects with visible skin disease, tattoos, skin condition, or abnormal skin color
mass accumulation rate (mar) as a predictive biomarker in multiple myeloma

Conditions: Multiple Myeloma in Relapse

Summary: this study will collect bone marrow (bm) aspirate samples from patients with relapsed refractory multiple myeloma (rrmm) prior to the start of a new treatment regimen for the purposes of prospectively measuring single-cell mass accumulation rate (mar) as a biomarker of patient response to that regimen. the primary study objective is to explore whether the single-cell mar biomarker can predict patient response in rrmm patients. in order to enable this primary objective, two patient cohorts will be required. first, a small vanguard cohort of patients with treatment naïve disease to define drug concentrations used for testing, and second, the main rrmm patient cohort. data will be collected to estimate the biomarker's predictive properties (accuracy, sensitivity, specificity), and to support improvement of the mar biomarker through additional research and discovery within the study dataset.


Eligibility criteria:
inclusion criteria: 1. written informed consent provided by patient 2. mm, with the following conditions: (closed) \*for patients in the vanguard cohort\* 1. treatment naïve disease with bm clinically indicated \*for patients in the rrmm cohort\* 1. relapsed/refractory disease with bm samples clinically indicated 2. within 4-weeks prior to initiation of 2nd-line or later therapy 3. patient's oncologist must be planning to change the patient's next line of treatment to a monotherapy or combination therapy composed exclusively of drugs from the following list: bortezomib (velcade), carfilzomib (kyprolis), lenalidomide (revlimid), pomalidomide (pomalyst), cyclophosphamide (cytoxan), dexamethasone, ixazomib (ninlaro), venetoclax (venclexta), selinexor (xpovio) exclusion criteria: 1. unable or unwilling to provide informed consent 2. daratumumab/elotuzumab or other antibody-based therapeutic regimens as immediately planned treatment (as prior therapy is acceptable) 3. patient enrolled/enrolling in a clinical trial where data or specimen sharing provisions preclude use in this study 4. prior exposure to car-t therapy 5. prior allogeneic stem cell transplant 6. has received any systemic chemotherapy or rt, including palliative, within 7 days prior to bm biopsy 7. has received any ab therapy within 4 weeks prior to bm biopsy

Keywords: functional biomarker multiple myeloma phenotypic biophysical
branched chain amino acid plus glucose supplement reduces exercise-induced delayed onset muscle soreness in college females

Conditions: Exercise-induced Delayed Onset Muscle Soreness

Summary: the purpose of this study is to determine if a dietary supplement containing branched chain amino acids will reduce the muscle soreness that sometimes occurs in the days following exercise.

supplementation with branched chain amino acids (bcaas) has been used to stimulate muscle protein synthesis following exercise. the purpose of this study was to determine if supplementation with bcaas in combination with glucose would reduce exercise-induced delayed onset muscle soreness (doms). using a double-blind crossover design, 20 subjects (11 females, 9 males) were randomly assigned to either bcaa (n=10) or placebo (n=10) groups. subjects performed a squatting exercise to elicit doms and rated their muscle soreness every 24 hours for four days following exercise while continuing to consume the bcaa or placebo. following a three-week recovery period, subjects returned and received the alternate bcaa or placebo treatment, repeating the same exercise and doms rating protocol for the next four days. bcaa supplementation in female subjects resulted in a significant decrease in doms versus placebo at 24 hours following exercise (p = 0.018). no significant effect of bcaa supplementation versus placebo was noted in male subjects, nor when male and female results were analyzed together. this gender difference may be related to dose per body weight differences between male and female subjects.

Eligibility criteria:
inclusion criteria: * men (n=9) and women (n=11) aged 18-25 who engaged in no more than one hour of light to moderate intensity physical activity per week were recruited from the greater burlington, vermont area. exclusion criteria: * individuals who engaged in more than one hour per week of light to moderate physical activity * had been involved in strict athletic competition or weight training in the past six months * were pregnant or nursing, had a known muscular disease, diabetes mellitus, cardiovascular disease, respiratory disease, and/or were currently taking a protein-based dietary supplement

Keywords: branched chain amino acids, exercise, delayed onset muscle soreness
ethanol-induced vestibular dysfunction as a model for bilateral vestibular syndrome.

Conditions: vHIT- and VOG-model for Bilateral Vestibular Neuronitis

Summary: the purpose of the study is to create a vhit- and vog-model for bilateral vestibular neuronitis, via ethanol administration in healthy human subjects.

ethanol administration has an effect on vestibular function, measurable with video head impulse test (vhit)- and vestibulo-oculography (vog)-methods. the purpose of the study is to create a vhit- and vog-model for bilateral vestibular neuronitis, a disease with difficult diagnostics, via ethanol administration in healthy human subjects. as subjects are consuming ethanol via oral route, vhit-measurements and vog-measurements (slow and rapid eye movement recordings) are being recorded in order to measure the change in vestibular function. during approx. 5 hours, 4 vhit measurements will take place, while subjects ingest ethanol towards 1 per mille levels, measured via alcoholmeter. necessary precautions include strict exclusion criteria regarding health of the subjects and also comprehensive preparedness for management of allergic reactions and other unusual phenomena related to alcohol consumption.

Eligibility criteria:
inclusion criteria: * no previous ear diseases * normal hearing * no signs of alcohol dependence (6 points or less in audit-questionnaire) exclusion criteria: * previous ear diseases * abnormal hearing * signs of alcohol dependence (7 points or more in audit-questionnaire)

Keywords: vhit vestibular neuronitis vog
spinal cord stimulation for gait in parkinson disease

Conditions: Parkinson Disease; Atypical Parkinsonism

Summary: balance and gait impairment increases the risk of falls and contributes to a reduced quality of life and shorter survival in parkinson disease (pd) and atypical parkinsonism patients. in preliminary case studies, electrical epidural spinal cord stimulation (scs) has been shown to significantly improve gait, postural instability, rigidity, and tremor. controlled studies for optimizing which stimulation settings produce the best clinical response for mobility and gait, and achieving these results chronically are all significant unmet needs. using quantitative laboratory and mobile technologies to test a range of stimulation settings, this research study aims to determine which scs parameters or combination of parameters is best suited to effectively alleviate disabling symptoms experienced by each patient.


Eligibility criteria:
inclusion criteria: * consenting male and female participants, aged 18 years to 80 years * idiopathic pd with ii-iv hoehn-yahn stage * a history of frequent falls, gait and balance dysfunction and postural instability * on-freezing * ability to perform a gait/walking task (under close supervision), * pd participants referred by dr. jog to the functional neurosurgeon for scs implantation for treatment of their gait and balance dysfunction and/or for their freezing of gait. * scs eligibility has been confirmed by neurologist and neurosurgeon * patients who receive scs for their gait and mobility must participate in this study in order to determine which scs parameters provide the patient with the best outcome for their pd symptoms. * able to give informed consent * able to attend all clinic visits and assessments * no dementia or psychiatric abnormalities on neuropsychological testing * no significant secondary causes (such as cerebrovascular disease, normal pressure hydrocephalus, peripheral neuropathy, severe degenerative lower limb or back disease). * we had a few devices to include exploratory trial in atypical pd (msa, psp, and cbd confirmed diagnosis from clinic). exclusion criteria: * history of stroke * history of als or myasthenia gravis * offending medications (lithium, valproate, steroids, amiodarone, beta-adrenergic agonists (e.g. salbutamol). * persons prescribed zonisamide * women reporting that they are pregnant * persons medically unstable with contraindications to scs will be excluded * previous brain surgery or cardiac pacemaker * eligibility for deep brain stimulation surgery * moderately severe parkinsonism in the context of unstable pharmacological treatment * dementia as assessed by dsm criteria or severe cognitive disturbances * severe psychiatric symptoms (in particular, hallucinations and depression) * bad general health * lack of compliance at follow-up * severe dyskinesias * significant cognitive impairment

Keywords: spinal cord stimulation gait analysis whole-body kinematics parkinson's disease neuromodulation feature extraction